Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Total Non-Current Liabilities: 2016-2025

Historic Total Non-Current Liabilities for Tg Therapeutics (TGTX) over the last 8 years, with Sep 2025 value amounting to $415.8 million.

  • Tg Therapeutics' Total Non-Current Liabilities rose 6.41% to $415.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $415.8 million, marking a year-over-year increase of 6.41%. This contributed to the annual value of $351.5 million for FY2024, which is 108.34% up from last year.
  • As of Q3 2025, Tg Therapeutics' Total Non-Current Liabilities stood at $415.8 million, which was down 1.92% from $424.0 million recorded in Q2 2025.
  • Tg Therapeutics' Total Non-Current Liabilities' 5-year high stood at $424.0 million during Q2 2025, with a 5-year trough of $97.5 million in Q3 2021.
  • Over the past 3 years, Tg Therapeutics' median Total Non-Current Liabilities value was $371.2 million (recorded in 2024), while the average stood at $324.9 million.
  • Per our database at Business Quant, Tg Therapeutics' Total Non-Current Liabilities declined by 5.19% in 2022 and then soared by 108.34% in 2024.
  • Over the past 5 years, Tg Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $142.1 million in 2021, then decreased by 5.19% to $134.7 million in 2022, then rose by 25.22% to $168.7 million in 2023, then surged by 108.34% to $351.5 million in 2024, then grew by 6.41% to $415.8 million in 2025.
  • Its last three reported values are $415.8 million in Q3 2025, $424.0 million for Q2 2025, and $417.2 million during Q1 2025.